



PRESS RELEASE

PR. No 355/2016

**INTRAVENOUS INFUSIONS LIMITED (IIL) –
UN-AUDITED FINANCIAL STATEMENTS
FOR THE THIRD QUARTER ENDING SEPTEMBER 2016**

IIL has released its un-audited Financial Statements for the third quarter ending September 30, 2016 as per the attached.

Issued in Accra, this 4th
day of November, 2016

- E N D -

att'd.

Distribution:

1. All LDMs
2. General Public
3. Listed Companies
- 4 Registrars, Custodians
5. GSE Securities Depository
6. SEC
7. GSE Council Members
8. GSE Notice Board

For enquiries, contact:

**General Manager/Head of Listings, GSE on 0302 669908, 669914,
669935**

**JEB*



INTRAVENOUS INFUSIONS PLC
KEY FINANCIAL HIGHLIGHTS

	SEPTEMBER, 2016	SEPTEMBER, 2015
	UNAUDITED	UNAUDITED
	GHC	GHC
Revenue	7,433,207	5,528,352
Gross profit	3,730,120	2,509,984
Operating profit/(loss) before interest and tax	1,460,151	453,159
Net Profit/(loss)	1,095,632	(83,095)
Finance cost	364,519	536,254
Depreciation	213,035	174,591
Foreign exchange losses	76,592	424,029
Total Assets	12,361,738	10,063,557
Net Assets	7,620,557	318,602



INTRAVENOUS INFUSIONS PLC
UNAUDITED PROFIT AND LOSS FOR THE PERIOD ENDED 30TH SEPTEMBER 2016

	SEPTEMBER, 2016	SEPTEMBER, 2015
	UNAUDITED	UNAUDITED
	GHC	GHC
Revenue	7,433,207	5,528,352
Cost of operations	<u>(3,703,087)</u>	<u>(3,018,368)</u>
Gross profits	3,730,120	2,509,984
Other Income	<u>8,107</u>	<u>7,582</u>
	3,738,227	2,517,566
Operating and other expenses	<u>(2,278,076)</u>	<u>(2,064,407)</u>
Profit before finance cost and tax	1,460,151	453,159
Finance cost	<u>(364,519)</u>	<u>(536,254)</u>
Profit/(loss) before tax	1,095,632	(83,095)
Taxation	<u>(205,431)</u>	<u>-</u>
Net profit/(loss) after tax	<u>890,201</u>	<u>(83,095)</u>



INTRAVENOUS INFUSIONS PLC
UNAUDITED BALANCE SHEET AS AT 30TH SEPTEMBER 2016

	SEPTEMBER, 2016	SEPTEMBER, 2015
	UNAUDITED	UNAUDITED
	GHC	GHC
ASSETS		
NON CURRENT ASSETS		
Property, Plant and Equipment	<u>3,982,233</u>	<u>3,668,026</u>
CURRENT ASSETS		
Inventory	1,768,864	1,515,057
Trade and Other Receivables	6,416,229	4,713,437
Taxation	55,118	123,407
Cash & Bank	<u>139,294</u>	<u>43,630</u>
	<u>8,379,505</u>	<u>6,395,531</u>
Total Asstes	<u>12,361,738</u>	<u>10,063,557</u>
EQUITY AND LIABILITIES		
CAPITAL AND RESERVES		
Stated Capital	7,213,384	570,520
Income Surplus	(2,266,658)	(2,720,318)
Capital Surplus	<u>2,468,400</u>	<u>2,468,400</u>
	<u>7,415,126</u>	<u>318,602</u>
NON CURRENT LIABILITIES		
Employee Benefit Obligation	1,067,808	919,028
Deferred Taxation	<u>616,689</u>	<u>652,217</u>
	<u>1,684,497</u>	<u>1,571,245</u>
CURRENT LIABILITIES		
Trade and Other Payables	1,472,259	6,516,884
Bank Overdraft	<u>1,789,856</u>	<u>1,656,826</u>
	<u>3,262,115</u>	<u>8,173,710</u>
Total Equity and Liabilities	<u>12,361,738</u>	<u>10,063,557</u>



INTRAVENOUS INFUSIONS PLC

UNAUDITED CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER 2016

	SEPTEMBER, 2016	SEPTEMBER, 2015
	UNAUDITED	UNAUDITED
	GHC	GHC
Net Profit from operation before tax	1,095,632	(83,095)
Adjustment for:		
Employee Benefits Costs	46,348	(9,141)
Depreciation	213,035	174,591
Operating cash flow before movement in working capital	1,355,015	82,355
Decrease/(Increase) in inventory	(514,453)	(455,383)
Decrease/(Increase) in Receivables	(1,244,618)	(446,963)
Increase/(Decrease) in Payables	(4,066,486)	590,605
Tax (paid)/refund	(100,057)	(7,749)
	(5,925,614)	(319,490)
Cash generated from operations	(4,570,599)	(237,135)
Investing activities		
Sale of Property Plant and Equipment	-	-
Purchase of Property Plant and Equipment	(562,181)	(47,477)
	(562,181)	(47,477)
Financing activities		
Proceeds from issue of shares		
Reduction in Capital Surplus		
Bank Overdraft	1,789,856	94,944
Net cash from financing activities	1,789,856	94,944
Net increase/(decrease) in cash and cash equivalent	(3,342,924)	(189,668)
cash and cash equivalent at the beginning of the year	3,482,218	233,298
Bank and cash balances	139,294	43,630



INTRAVENOUS INFUSIONS PLC

UNAUDITED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30TH SEPTEMBER 2016

	STATED CAPITAL GH¢	INCOME SURPLUS GH¢	CAPITAL SURPLUS GH¢	TOTAL GH¢
Balance at January 1, 2016	7,213,184	(3,156,859)	2,468,400	6,524,725
Profit for the period	-	890,201	-	890,201
Balance at September 30, 2016	<u>7,213,184</u>	<u>(2,266,658)</u>	<u>2,468,400</u>	<u>7,414,926</u>



To the above accounts have been prepared in accordance with International Financial Reporting Standards and in compliance with the companies code 1963, (Act 179).

Best of our knowledge the Financial Statements do not contain any untrue statements or misleading facts and no material facts have been omitted

LEON APPENTENG
DIRECTOR

ISAAC OSEI
CHAIRMAN